GIS — General Mills, Inc.

The tape is unambiguously negative. As of 2026-09-23 the shares were down 11.31% over one month and 3.09% over one week, trading 7.02% below the 20-day SMA, 6.20% below the 50-day and 9.82% below the 200-day, in the bottom quartile of the $31.75-$51.33 52-week range. The Q1 FY27 report (filed 2026-09-23) beat on adjusted EPS but showed net sales -3% YoY to $4.39B, adjusted operating margin of ~14.4% (roughly 134bp below the prior-year adjusted level), and adjusted operating profit down 11% in constant currency to $634M on sticky input costs and lower volumes; management reaffirmed FY27 EPS of $3.00-$3.20 instead of lifting it. Sell-side is only neutral (Hold consensus; 22 holds, 8 buys, 6 sells; $35.92 consensus target, essentially the current price), and the 6.74% dividend yield - roughly double GIS's historical norm - tells you the market is pricing genuine risk to the payout, not a temporary dip.

Revenue: headline net sales went -6.8% YoY in Q1 FY26 ($4,517.5M), -7.2% in Q2 FY26 ($4,860.8M), -8.4% in Q3 FY26 ($4,436.7M), +1.2% in Q4 FY26 ($4,609.6M), then -2.8% in Q1 FY27 ($4,389.5M). That apparent improvement is portfolio-driven (the U.S. yogurt divestiture annualizing, Brazil sale), not organic - management says organic net sales were flat in Q1 FY27. The top line is stabilizing at a flat level, not recovering. Margins are the real story: quarterly operating margin fell from 20.57% (Q2 FY25) and 18.41% (Q3 FY25) to 14.98% (Q2 FY26) and 12.29% (Q3 FY26), and Q1 FY27's 14.43% ($633.6M / $4,389.5M) is ~134bp below the ~15.8% adjusted Q1 FY26 figure once you strip the ~$1.0B divestiture gain that inflated reported Q1 FY26 operating income to $1,725.8M (38.2% margin). Earnings prints are partly noise: Q4 FY26 booked a $2,007.9M net loss (EPS -$3.74) on a large one-time charge, which is why TTM EPS is -$1.665. Cash flow is deteriorating cleanly: Q1 FY27 FCF of $207.3M is 27.9% below Q1 FY26's $287.5M, and FY26 FCF of $1,626M was ~29% below FY25's $2,293M. Verdict: decelerating, not inflecting - revenue has stopped falling organically but margins keep compressing and free cash flow is shrinking. That is a real operating squeeze, not a one-quarter blip.

As of 2026-09-23, GIS at $35.45 is cheap on every metric that isn't broken. The trailing P/E of -21.49 and TTM EPS of -$1.665 are artifacts of the Q4 FY26 write-down and should be ignored; on the $3.075 consensus forward EPS the stock trades at ~11.5x, versus a 5-year average P/E of 15.92x - a ~28% discount. P/S is 1.03x versus a 5-year average of 1.85x, EV/EBITDA is 10.65x, PEG is 0.285, and the dividend yield is 6.74%, roughly double the norm. The catch: the discount is explainable rather than obviously mispriced. Organic sales are flat, adjusted operating profit is shrinking, FCF is down ~28% YoY, net debt is ~$13.2B against ~$3.0B of EBITDA (leverage around 4x on the supplied data), and the ~$1.27B annual dividend consumes ~82% of TTM free cash flow of $1.55B. Verdict: cheap, but cheap for identifiable reasons - the valuation is a bet on margins troughing and the dividend surviving, not a free lunch.

The market is pricing roughly zero growth plus some probability of a dividend reset. At 11.5x forward earnings and a 6.74% yield, the stock embeds an assumption that EPS stays pinned near $3.00-$3.20 and that the payout is at risk. Two live paths: (a) if FY27 adjusted EPS lands at the $3.10 midpoint, the ~$2.39 dividend is maintained, and input costs ease, the multiple can re-rate toward 12.5-13x - roughly $39-40 - with no earnings growth required; (b) if organic sales stay flat and adjusted operating margin keeps sliding 100-150bp a year, EPS drifts to the low end of guidance, FCF falls toward the ~$1.3B dividend cost line, and the 6.7% yield becomes a value trap that gets cut rather than paid. The most informative number each quarter is free cash flow versus that ~$1.3B annual dividend line, not the EPS print - and Q1 FY27's $207M FCF was well below a pro-rata pace.

As of 2026-09-23, RSI(14) stood at 35.18 - weak, but not yet the sub-30 oversold reading that has historically marked tradeable lows in this name. Price was 7.02% below the 20-day SMA, 6.20% below the 50-day and 9.82% below the 200-day: a confirmed downtrend with all three averages stacked against it. Momentum is negative on every meaningful horizon except three months (+2.96%): -3.09% one-week, -11.31% one-month, -3.67% six-month. At $35.45 the stock sits roughly 10% above its 52-week low of $31.75 and in the bottom quartile of the $31.75-$51.33 range. Entry timing: there is no reversal signal here - no higher low, no reclaim of the 20-day, no positive RSI divergence. A disciplined approach is to wait for RSI to push below 30 and then confirm with a close back above the 20-day SMA rather than catching a falling knife into the December earnings print.

• Value-seeking consumer behavior: low-to-middle-income households are trading down and shrinking baskets, depressing packaged-food volumes across North American retail - visible in GIS's flat organic sales against a 3% headline decline.
• Sticky input-cost inflation: commodity inflation has cooled from its peak but ingredient, packaging and freight costs still pressure gross margins, contributing to the 11% constant-currency drop in Q1 FY27 adjusted operating profit alongside volume deleverage.
• GLP-1/obesity-drug adoption and shifting dietary preferences: a multi-year structural overhang on center-of-store, highly processed categories where GIS's cereal, baking and convenient-meal brands are concentrated.
• Private-label share gains and retailer power: grocery chains keep expanding own-brand offerings, limiting GIS's pricing power and shelf space precisely when unit volumes are weak.
• Interest rates and income-investor competition: GIS carries roughly $13.6B gross and $13.2B net debt (debt/equity 1.83), so refinancing costs matter, while a 6.74% equity yield competes directly against bond yields for income buyers - a comparison that gets less favorable in a higher-for-longer rate backdrop.

• FY27 Q2 earnings, expected mid-to-late December 2026 - the next real checkpoint on holiday retail volumes, margin trajectory and progress against the $750M FY27 cost-savings target.
• Closure of the Mainland China Häagen-Dazs Shops divestiture before the end of calendar 2026, and how proceeds are deployed (debt paydown would be the most thesis-supportive use).
• Follow-through on the Brazil business sale to Café Três Corações (completed 2026-09-02, R$800M base price) and any further portfolio pruning that lifts consolidated margin.
• Dividend declaration and any increase - with the stock at a 6.74% yield and the payout consuming ~82% of TTM free cash flow, management's treatment of the dividend is the single biggest swing factor for sentiment.
• Evidence of an input-cost peak combined with delivery of the $750M Holistic Margin Management savings - the first quarter where adjusted operating margin stops falling would be the genuine inflection signal.

• Dividend coverage: the ~$2.39/share payout costs roughly $1.27B a year against TTM FCF of $1.55B (~82%); a cut or extended freeze would likely force a sharp de-rating given how central the yield is to the current shareholder base.
• Continued organic volume weakness: flat organic sales are being held up by price/mix while units decline - if price/mix rolls over, the revenue base shrinks outright.
• Margin compression that does not stop: adjusted operating profit fell 11% in constant currency in Q1 FY27, and HMM savings may keep getting offset by volume deleverage and cost inflation.
• Balance-sheet fragility: debt/equity 1.83, LT debt/equity 1.66, current ratio 0.70, quick ratio 0.39, net debt ~$13.2B against ~$3.0B of EBITDA (~4x) - weak liquidity for a staples company.
• Further write-down risk: the $2.0B Q4 FY26 charge shows goodwill and intangibles (notably pet/Blue Buffalo and international assets) are carried at values current earnings power may not support.
• Competitive displacement by private label and by better-positioned large-cap staples peers, which caps both volume recovery and pricing.

GIS is a genuinely cheap staples stock - ~11.5x forward earnings, a 6.7% dividend yield, a 28% discount to its own 5-year average P/E - but the cheapness is earned rather than accidental: organic sales are flat, adjusted operating profit fell 11% YoY in Q1 FY27, free cash flow is down roughly 28% YoY, and ~$13.2B of net debt leaves the dividend soaking up over 80% of free cash flow. This is an income/value bet on margins troughing and the payout surviving, not a growth story, and the December FY27 Q2 print plus the next dividend decision are the events that settle it. At $35.45 with no technical reversal signal and a real dividend-reset scenario pointing to the low $30s, the risk/reward does not yet justify buying the yield.

I applied a 12.5x forward P/E - a ~21% discount to GIS's 5-year average of 15.92x, reflecting flat organic sales, ~4x net leverage and the packaged-food sector's de-rating - to management's reaffirmed FY27 adjusted EPS guidance midpoint of $3.10 (the $3.075 analyst consensus rounds to essentially the same figure), giving $38.75. Cross-checks support that level rather than a higher one: 11.5x EV/EBITDA on ~$3.0B of EBITDA less ~$13.2B of net debt implies roughly $40/share, and a Gordon-growth dividend model ($2.39 dividend, 3% growth, 9% required return) implies ~$39.80 - so I took a modest haircut for dividend-sustainability risk instead of the higher readings.